182 related articles for article (PubMed ID: 27756228)
1. Drug discovery using clinical outcome-based Connectivity Mapping: application to ovarian cancer.
Raghavan R; Hyter S; Pathak HB; Godwin AK; Konecny G; Wang C; Goode EL; Fridley BL
BMC Genomics; 2016 Oct; 17(1):811. PubMed ID: 27756228
[TBL] [Abstract][Full Text] [Related]
2. Identifying prognostic signature in ovarian cancer using DirGenerank.
Wang JY; Chen LL; Zhou XH
Oncotarget; 2017 Jul; 8(28):46398-46413. PubMed ID: 28615526
[TBL] [Abstract][Full Text] [Related]
3. Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line.
Teng PN; Bateman NW; Wang G; Litzi T; Blanton BE; Hood BL; Conrads KA; Ao W; Oliver KE; Darcy KM; McGuire WP; Paz K; Sidransky D; Hamilton CA; Maxwell GL; Conrads TP
Hum Cell; 2017 Jul; 30(3):226-236. PubMed ID: 28251557
[TBL] [Abstract][Full Text] [Related]
4. Apoptosis-based evaluation of chemosensitivity in ovarian cancer patients.
Flick MB; O'Malley D; Rutherford T; Rodov S; Kamsteeg M; Hao XY; Schwartz P; Kacinski BM; Mor G
J Soc Gynecol Investig; 2004 May; 11(4):252-9. PubMed ID: 15120700
[TBL] [Abstract][Full Text] [Related]
5. Gene expression and prognostic significance in ovarian cancer.
Tammela J; Odunsi K
Minerva Ginecol; 2004 Dec; 56(6):495-502. PubMed ID: 15729202
[TBL] [Abstract][Full Text] [Related]
6. Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer.
Dizon DS; Hensley ML; Poynor EA; Sabbatini P; Aghajanian C; Hummer A; Venkatraman E; Spriggs DR
J Clin Oncol; 2002 Mar; 20(5):1238-47. PubMed ID: 11870166
[TBL] [Abstract][Full Text] [Related]
7. Targeting of topoisomerases for prognosis and drug resistance in ovarian cancer.
Bai Y; Li LD; Li J; Lu X
J Ovarian Res; 2016 Jun; 9(1):35. PubMed ID: 27315793
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapeutic drug sensitivity of primary cultures of epithelial ovarian cancer cells from patients in relation to tumour characteristics and therapeutic outcome.
von Heideman A; Tholander B; Grundmark B; Cajander S; Gerdin E; Holm L; Axelsson A; Rosenberg P; Mahteme H; Daniel E; Larsson R; Nygren P
Acta Oncol; 2014 Feb; 53(2):242-50. PubMed ID: 23713890
[TBL] [Abstract][Full Text] [Related]
9. Expression signature distinguishing two tumour transcriptome classes associated with progression-free survival among rare histological types of epithelial ovarian cancer.
Wang C; Winterhoff BJ; Kalli KR; Block MS; Armasu SM; Larson MC; Chen HW; Keeney GL; Hartmann LC; Shridhar V; Konecny GE; Goode EL; Fridley BL
Br J Cancer; 2016 Jun; 114(12):1412-20. PubMed ID: 27253175
[TBL] [Abstract][Full Text] [Related]
10. Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent drug candidates for cancer treatment.
Nagaraj AB; Wang QQ; Joseph P; Zheng C; Chen Y; Kovalenko O; Singh S; Armstrong A; Resnick K; Zanotti K; Waggoner S; Xu R; DiFeo A
Oncogene; 2018 Jan; 37(3):403-414. PubMed ID: 28967908
[TBL] [Abstract][Full Text] [Related]
11. The Prognostic 97 Chemoresponse Gene Signature in Ovarian Cancer.
Matondo A; Jo YH; Shahid M; Choi TG; Nguyen MN; Nguyen NNY; Akter S; Kang I; Ha J; Maeng CH; Kim SY; Lee JS; Kim J; Kim SS
Sci Rep; 2017 Aug; 7(1):9689. PubMed ID: 28851888
[TBL] [Abstract][Full Text] [Related]
12. Development and validation of an immune gene-set based Prognostic signature in ovarian cancer.
Shen S; Wang G; Zhang R; Zhao Y; Yu H; Wei Y; Chen F
EBioMedicine; 2019 Feb; 40():318-326. PubMed ID: 30594555
[TBL] [Abstract][Full Text] [Related]
13. Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients.
Mignogna C; Staropoli N; Botta C; De Marco C; Rizzuto A; Morelli M; Di Cello A; Franco R; Camastra C; Presta I; Malara N; Salvino A; Tassone P; Tagliaferri P; Barni T; Donato G; Di Vito A
J Ovarian Res; 2016 May; 9(1):31. PubMed ID: 27209210
[TBL] [Abstract][Full Text] [Related]
14. A gene-signature progression approach to identifying candidate small-molecule cancer therapeutics with connectivity mapping.
Wen Q; Kim CS; Hamilton PW; Zhang SD
BMC Bioinformatics; 2016 May; 17(1):211. PubMed ID: 27170106
[TBL] [Abstract][Full Text] [Related]
15. Global methylation profiling in serous ovarian cancer is indicative for distinct aberrant DNA methylation signatures associated with tumor aggressiveness and disease progression.
Keita M; Wang ZQ; Pelletier JF; Bachvarova M; Plante M; Gregoire J; Renaud MC; Mes-Masson AM; Paquet ÉR; Bachvarov D
Gynecol Oncol; 2013 Feb; 128(2):356-63. PubMed ID: 23219462
[TBL] [Abstract][Full Text] [Related]
16. Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer.
Baron AT; Lafky JM; Boardman CH; Balasubramaniam S; Suman VJ; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):129-37. PubMed ID: 10067810
[TBL] [Abstract][Full Text] [Related]
17. Advances in the management of epithelial ovarian cancer.
Berkenblit A; Cannistra SA
J Reprod Med; 2005 Jun; 50(6):426-38. PubMed ID: 16050567
[TBL] [Abstract][Full Text] [Related]
18. Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer.
Karam AK; Chiang JW; Fung E; Nossov V; Karlan BY
Gynecol Oncol; 2009 Aug; 114(2):246-52. PubMed ID: 19500821
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
20. High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway.
Yoshihara K; Tsunoda T; Shigemizu D; Fujiwara H; Hatae M; Fujiwara H; Masuzaki H; Katabuchi H; Kawakami Y; Okamoto A; Nogawa T; Matsumura N; Udagawa Y; Saito T; Itamochi H; Takano M; Miyagi E; Sudo T; Ushijima K; Iwase H; Seki H; Terao Y; Enomoto T; Mikami M; Akazawa K; Tsuda H; Moriya T; Tajima A; Inoue I; Tanaka K;
Clin Cancer Res; 2012 Mar; 18(5):1374-85. PubMed ID: 22241791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]